title: Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment.
abstract: Nonadherence to prescribed medication is a common barrier to effective treatment, and current options to determine adherence are limited. This study describes development of an aggregate adherence measure based on population pharmacokinetics (PK), and its comparison to a subjective questionnaire, the Morisky 8-item medication adherence scale (MMAS8), in a trial of psychiatric patients on stable doses of oral aripiprazole. A comprehensive model was first built using plasma drug concentration data from 24 clinical studies comprising 448 patients with over 13,500 observations. Application of this model to independent patient profiles for a given drug-dosing regimen were used to generate the primary aggregate adherence metric, a ratio of observed versus expected plasma exposures at steady-state. Although the metric is capable of comparing relative adherence across groups, simulations showed that the metric is not sufficiently sensitive as an individual diagnostic in all cases. There were no trends observed between results from calculated aggregate adherence metrics and total scores from MMAS8 in a single-visit clinical trial of 47 patients with bipolar 1 disorder or schizophrenia who were on stable doses of aripiprazole, although a strong association was observed for one MMAS8 question. The range of the metric calculated for patients was between 0.16 and 3.15. The described approach of a novel "reverse" application of population PK to quantify relative adherence with an aggregate measure may be influential for both clinical and pharmacometric communities.
authors.affiliation: Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center Blvd. Suite 300, Princeton, NJ, 08540, USA, Jonathan.Knights@otsuka-us.com.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Knights
authors.forename: Shashank
authors.initials: S
authors.lastname: Rohatagi
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000097:blood* / Q000627:therapeutic use; D000068180:Aripiprazole / Q000097:blood* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D008954:Models, Biological; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D000068180:Aripiprazole
references.citation: Int J Qual Health Care. 1999 Jun;11(3):187-92
references.pmid: 10435838
references.citation: J Psychosom Res. 2010 Dec;69(6):591-9
references.pmid: 21109048
references.citation: Clin Pharmacol Ther. 2004 Nov;76(5):441-51
references.pmid: 15536459
references.citation: Arch Gen Psychiatry. 1995 Mar;52(3):173-88
references.pmid: 7872841
references.citation: Am J Psychiatry. 2011 Mar;168(3):286-92
references.pmid: 21205805
references.citation: Med Care. 2002 Aug;40(8):630-9
references.pmid: 12187177
references.citation: Clin Pharmacol Ther. 2014 Jun;95(6):617-26
references.pmid: 24739446
references.citation: J Clin Psychiatry. 2002 May;63(5):384-90
references.pmid: 12019661
references.citation: J Pharmacokinet Pharmacodyn. 2014 Jun;41(3):279-89
references.pmid: 24952228
references.citation: World Psychiatry. 2013 Oct;12(3):216-26
references.pmid: 24096780
references.citation: Psychiatr Serv. 2007 Sep;58(9):1187-92
references.pmid: 17766564
references.citation: Arch Gen Psychiatry. 1999 Mar;56(3):241-7
references.pmid: 10078501
references.citation: Annu Rev Pharmacol Toxicol. 2012;52:275-301
references.pmid: 21942628
references.citation: Value Health. 2008 Jan-Feb;11(1):48-56
references.pmid: 18237360
references.citation: J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
references.pmid: 18453793
references.citation: Clin Pharmacol Ther. 2012 Nov;92(5):575-83
references.pmid: 23033116
references.citation: Clinicoecon Outcomes Res. 2011;3:63-72
references.pmid: 21935334
references.citation: J Clin Psychiatry. 2003;64 Suppl 16:3-9
references.pmid: 14680412
references.citation: Clin Pharmacol Ther. 2000 Apr;67(4):331-4
references.pmid: 10801240
references.citation: Dan Med Bull. 2007 Nov;54(4):306-69
references.pmid: 18208680